Due to the weak expression of CD37 in normal T cells, CAR-T cells targeting CD37 for the treatment of T-cell lymphomas are expected to minimize the risk of autophagy and impaired T-cell regeneration. Here, CD37 is linked to T-cell non-Hodgkin lymphoma.